Invention Grant
- Patent Title: Indoleamine 2,3-dioxygenase based immunotherapy
- Patent Title (中): 吲哚胺2,3-双加氧酶基免疫疗法
-
Application No.: US12988124Application Date: 2009-04-17
-
Publication No.: US09433666B2Publication Date: 2016-09-06
- Inventor: Mads Hald Andersen , Per Thor Straten
- Applicant: Mads Hald Andersen , Per Thor Straten
- Applicant Address: DK Copenhagen N
- Assignee: IO Bioech ApS
- Current Assignee: IO Bioech ApS
- Current Assignee Address: DK Copenhagen N
- Agency: Merchant & Gould P.C.
- Priority: DK200800565 20080417
- International Application: PCT/DK2009/000095 WO 20090417
- International Announcement: WO2009/143843 WO 20091203
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K39/00 ; A61K38/19 ; A61K38/20

Abstract:
The present invention relates to the field of prophylaxis and therapy of cancer. In particular there is provided a protein Indoleamine 2,3-dioxygenase (IDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of DO or peptides derived here from or IDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to IDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above. The use of IDO and immunogenic peptide fragments hereof in cancer and infection treatment, diagnosis and prognosis is also provided.
Public/Granted literature
- US20110318372A1 INDOLEAMINE 2,3-DIOXYGENASE BASED IMMUNOTHERAPY Public/Granted day:2011-12-29
Information query